KOSPI large cap
Daewoong Pharmaceutical
A major Korean pharmaceutical company known for the botulinum toxin Nabota and gastrointestinal drugs. KOSPI large-cap constituent. Baseline node ahead of value-chain research; promoted to a full node once AI question demand is observed.
069620.KS Updated Jul 11, 2026 2 AI consumers
Annual return · 2026-07-10'21-13.5%'22+17.5%'23-27.5%'24+25%'25+23.1%YTD-21.9%
Money in ▸·
Daewoong Pharmaceutical~₩1.4T
▸ Money out·
Financials & Segments
- Total revenue · ~₩1.4T (FY2024)
- Segments · Prescription drugs (ETC) · OTC and Nabota
Revenue from
No refined links yet.
Pays to
No refined links yet.